AbbVie Inc. (NYSE:ABBV) is among the high growth mega cap stocks you can buy and hold for the next 3 years. Evan Seigerman, an analyst at BMO Capital, increased the price target on AbbVie Inc. (NYSE:ABBV) to $240 from$215 with an ‘Outperform’ rating. This potential upside of nearly 10% follows the company’s announcement that it has resolved litigation with generic drugmakers, allowing for the early market entry of generic Rinvoq. Many believe that generic competition market entry won’t occur until 2037, ...